The issuance of a U.S. patent for LEVOSIMENDAN represents a significant achievement for Tenax Therapeutics, enhancing its intellectual property portfolio and potentially increasing its competitiveness in the market for treatments of pulmonary hypertension with heart failure. This development could lead to increased investor confidence and a positive impact on the company's stock price in the short term.